Home > Rheumatology > EULAR 2019 > Axial Spondyloarthritis > NSAIDs Consumption Is Linked to Patient-assessed Disease Activity and Decreases with Use of Tnf Inhibitors

NSAIDs Consumption Is Linked to Patient-assessed Disease Activity and Decreases with Use of Tnf Inhibitors

Presented By
Dr Olafur Palsson, University Hospital Reykjavik, Iceland
Conference
EULAR 2019

Patients with inflammatory arthritis requiring TNF inhibitor (TNFi) therapy use more non-steroidal anti-inflammatory drugs (NSAIDs) than general population controls. However, NSAID consumption is significantly reduced following the initiation of a first-line biologic drug. Patients with the highest NSAID use have worse patient-reported outcome measures but physician outcome measures are similar, which may suggest a non-inflammatory mechanism of the pain.

TNFi therapy is effective in controlling several rheumatic diseases and more specifically has been shown to reduce pain. NSAIDs are commonly used for the management and treatment of pain and stiffness in inflammatory arthritides and are the first-line treatment for axial spondyloarthritis. Dr Olafur Palsson (University Hospital Reykjavik, Iceland) et al. aimed to gain a better understanding of the consumption of NSAIDs in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing sp...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on